Impressive results for acoziborole, a new single-dose oral drug: 95% efficacy against human African #trypanosomiasis (sleeping sickness caused by T.b. gambiense). An important step towards WHO's goal of elimination by 2030 #DNDI H/T @onisillos
https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00660-0/fulltext

Impressive results from small trial: Among the participants with late-stage sleeping sickness, acoziborole had a 95 per cent success rate, defined as no parasite being found in various bodily fluids at 18 months post-treatment. This rose to 100 per cent among those with an early to intermediate infection.

#trypanosomiasis

https://www.newscientist.com/article/2349078-drug-clears-sleeping-sickness-parasite-from-the-body-in-clinical-trial/

New research article in The Lancet Infectious Diseases> Efficacy and safety of #acoziborole in patients with human African #trypanosomiasis caused by #Trypanosoma brucei gambiense: a multicentre, open-label, single-arm, phase 2/3 trial https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(22)00660-0/fulltext #gambienseHAT #SleepingSickness

https://www.who.int/news/item/24-05-2022-benin--uganda-and-rwanda-eliminate-human-african-trypanosomiasis-as-a-public-health-problem #trypanosomiasis #UpliftingNews